Joao Cavalcante, MD
Cardiovascular Disease · Minneapolis, MNNPI 1841408226
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 30.5% of the total. 2025 is the largest year on record at $92,496, 2.1 times the $43,599 reported in 2019. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 467 payments — averaging $823.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$117K
- Boston Scientific$54K
- Medtronic$50K
- Abbott$39K
- Edwards Lifesciences$35K
- Novo Nordisk AS$31K
- plus $59K from 12 others
Across 100 payments — averaging $10,463 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$627K
- Edwards Lifesciences$410K
- Siemens Medical Solutions USA, Inc.$9K
What the payments were for
- Consulting fees$183,57948%
- Speaking & faculty fees$83,66422%
- Grants$3,5871%
- Travel & lodging$87,91423%
- Food & beverage$25,6357%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 82 | $117,370 |
| Boston Scientific | 53 | $53,710 |
| Medtronic(2 entities) | 103 | $49,891 |
| Abbott | 109 | $38,770 |
| Edwards Lifesciences | 77 | $34,543 |
| Novo Nordisk AS | 5 | $30,950 |
| Shockwave Medical, Inc | 4 | $28,283 |
| ZOLL Circulation Inc | 7 | $10,264 |
| W. L. Gore & Associates, Inc. | 2 | $7,905 |
| GE HealthCare | 7 | $6,088 |
| Heartflow, Inc. | 9 | $5,875 |
| Atricure, Inc. | 3 | $184 |
| Biosense Webster, Inc. | 1 | $120 |
| Bayer Healthcare LLC | 1 | $118 |
| Canon Medical Informatics, Inc. | 1 | $116 |
| Philips North America LLC | 1 | $102 |
| Jenavalve Technology, Inc. | 1 | $75 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STRUCTURAL HEART$31,247
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$28,197
- COREVALVE EVOLUT R$27,197
- ACUSON Origin Diagnostic Ultrasound System$25,695
- MitraClip System$25,438
- Edwards SAPIEN 3 Transcatheter Heart Valve$20,424
- CROSSBOSS$15,200
- TherOx DS2 Console$10,184
- Catheter$10,184
- Downstream Cartridge$10,184
- MAGNETOM Sola$8,544
- Product in Development$7,905
- FFRct$5,726
- MitraClip$1,014
- Watchman$1,000
- SAPIEN 3 Ultra RESILIA$992
- Mitra Clip system$963
- WATCHMAN Access System$751
- GENERAL - THERAPIES$602
- NAVITOR$348
How this compares
$384,378 in reported general payments places this provider in the 95th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 126 | $127,950 |
| FarxigaDapagliflozin Propanediol | 116 | $110,644 |
| EliquisApixaban | 80 | $79,545 |
| EntrestoSacubitril/Valsartan | 30 | $34,326 |
| XareltoRivaroxaban | 16 | $22,751 |
| MounjaroTirzepatide | 20 | $20,793 |
| Repatha SureclickEvolocumab | 13 | $18,150 |
| WegovySemaglutide | 13 | $16,494 |
| OzempicSemaglutide | 16 | $14,423 |
| Rosuvastatin Calcium | 190 | $2,769 |
| Metoprolol Succinate | 59 | $1,073 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 44 | $769 |
| Irbesartan | 27 | $693 |
| Atorvastatin Calcium | 46 | $593 |
| Amlodipine Besylate | 31 | $471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $15 | $34,32630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 451 cardiovascular disease providers in Minnesota.
Other cardiovascular disease in Minneapolis
- Jeffrey ChambersMinneapolis$3.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Nedaa SkeikMinneapolis$453K
- Inderjit AnandMinneapolis$384K
- David HurrellMinneapolis$205K
- Yader Sandoval PichardoMinneapolis$157K
- Charles HerzogMinneapolis$157K
- Tamas AlexyMinneapolis$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.